GSK announces the closure of its Dresden vaccine manufacturing facility due to market shifts.
According to Huxiu, GSK will shut down its Dresden vaccine plant, which has operated for 115 years and once produced 2 million doses of flu vaccine weekly for 70 countries. The decision follows a 26% decline in sales of its traditional Fluarix and FluLaval vaccines in 2025, and the company plans to launch an mRNA flu vaccine trial in September 2026.
Key facts
- 01GSK to close its Dresden plant built in 1911
- 02The plant produced 2 million flu vaccine doses per week and supplied 70 countries
- 03Fluarix and FluLaval sales fell 26% in 2025
- 04GSK plans an mRNA flu vaccine trial in September 2026
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.